Table of Contents

EXECUTIVE SUMMARY …………………………………………………………………………. ES-1
i. Cardiovascular diseases overview …………………………………………. ES-1
ii. Global vascular stents market ……………………………………………….. ES-1
a. Market drivers and limiters ……………………………………… ES-3
b. Device segment insights…………………………………………. ES-4
c. Technology trends …………………………………………………. ES-5
d. Market leaders ………………………………………………………. ES-5
e. Competitive strategies ……………………………………………. ES-6
f. Emerging competition …………………………………………….. ES-6
iii. Methodology ……………………………………………………………………….. ES-7

Exhibit ES-1: Vascular stents global market forecast, 2016-21 ………………………. ES-2
Exhibit ES-2: Global vascular stents market, share by country/region, 2016 ……. ES-3
Exhibit ES-3: Drivers and limiters of growth of the vascular stents market ………. ES-4

1. CARDIOVASCULAR DISEASES OVERVIEW …………………………………….. 1-1
1.1 Acute coronary syndrome ………………………………………………………… 1-3
1.1.1 Atherosclerosis ………………………………………………………… 1-4
1.1.2 Angina pectoris ………………………………………………………… 1-5
1.1.3 Myocardial infarction ………………………………………………… 1-6
1.1.4 Diagnosis and treatment………………………………………….. 1-10
1.2 Hypertension ……………………………………………………………………….. 1-10
1.3 Peripheral vascular disease …………………………………………………… 1-13
1.3.1 Critical limb ischemia ………………………………………………. 1-14
1.3.2 Aneurysm ……………………………………………………………… 1-14
1.3.3 Deep vein thrombosis/pulmonary embolism ……………….. 1-15
1.3.4 Diagnosis and treatment………………………………………….. 1-17
1.4 Cerebrovascular disease ……………………………………………………….. 1-18
1.4.1 Diagnosis and treatment………………………………………….. 1-21
1.5 Bibliography …………………………………………………………………………. 1-22

Exhibit 1-1: Estimated mortality due to ischemic heart disease and cerebrovascular disease, select countries ………………………………….. 1-1
Exhibit 1-2: Top 10 countries with the highest CVD death rates……………………… 1-2
Exhibit 1-3: Estimated incident cases for acute coronary syndrome, select countries ……………………………………………………………………… 1-4
Exhibit 1-4: Age-standardized incidence (000s) of angina pectoris, select regions ………………………………………………………………………… 1-6
Exhibit 1-5: Clinical classification of acute myocardial infarction ……………………. 1-7
Exhibit 1-6: Age-standardized incidence (000s) of acute myocardial infarction, select regions ………………………………………………………….. 1-9
Exhibit 1-7: Estimated incident cases of myocardial infarction, select countries .. 1-9
Exhibit 1-8: Estimated prevalent cases of hypertension, select countries ………. 1-12
Exhibit 1-9: Mortality attributable to hypertensive diseases, select countries ….. 1-12
Exhibit 1-10: Estimated incident cases of DVT, select countries …………………….. 1-16
Exhibit 1-11: Estimated incident cases of PE, select countries ………………………. 1-17
Exhibit 1-12: Estimated incident cases of stroke, select countries ………………….. 1-20
Exhibit 1-13: Estimated prevalent cases of stroke, select countries ………………… 1-20

2. VASCULAR STENT PRODUCTS ……………………………………………………… 2-1
2.1 Vascular stent products …………………………………………………………… 2-2
2.2 Vascular stents in development ………………………………………………… 2-9
2.3 Trends in vascular stent innovation …………………………………………. 2-12
2.4 Alternatives to vascular stent implantation ……………………………….. 2-13
2.5 Bibliography …………………………………………………………………………. 2-15

Exhibit 2-1: Advantages and disadvantages of stenting ………………………………… 2-2
Exhibit 2-2: Images of select vascular stents ………………………………………………. 2-3
Exhibit 2-3: Selected bare-metal stents and manufacturers …………………………… 2-4
Exhibit 2-4: Selected drug-eluting stents and manufacturers …………………………. 2-6
Exhibit 2-5: Advantages and disadvantages of BVSs ……………………………………. 2-7
Exhibit 2-6: Selected BVSs and manufacturers ……………………………………………. 2-9
Exhibit 2-7: Current clinical trials investigating stent devices ……………………….. 2-10
Exhibit 2-8: Selected drug-eluting BVSs in development …………………………….. 2-11
Exhibit 2-9: Information on selected non-drug-eluting BVSs in development ….. 2-12

3. VASCULAR STENTS MARKET ………………………………………………………… 3-1
3.1 Global market insights …………………………………………………………….. 3-1
3.1.1 Market value ……………………………………………………………. 3-2
3.1.2 Technology trends ……………………………………………………. 3-7
3.1.3 Market drivers and limiters ………………………………………. 3-10
3.1.4 Vascular stents overview …………………………………………. 3-13
3.1.5 Market leaders ……………………………………………………….. 3-15
3.1.6 Competitive strategies …………………………………………….. 3-16
3.1.7 Emerging competition ……………………………………………… 3-16
3.2 Global competitors ………………………………………………………………… 3-17
3.2.1 Bare-metal stents …………………………………………………… 3-17
3.2.2 Drug-eluting stents …………………………………………………. 3-18
3.3 Market forecast …………………………………………………………………….. 3-19
3.3.1 Market forecast: US ………………………………………………… 3-20
3.3.2 Market forecast: five major EU markets ……………………… 3-30
3.3.3 Market forecast: Japan ……………………………………………. 3-44
3.3.4 Market forecast: rest of the world ……………………………… 3-52
3.4 Bibliography …………………………………………………………………………. 3-63

Exhibit 3-1: Vascular stents, global market forecast, 2016-21 ………………………… 3-3
Exhibit 3-2: Vascular stent sales combined market forecast, by product segment ($m), 2016-21 …………………………………………………………… 3-4
Exhibit 3-3: Global vascular stents market, share by country/region, 2016 ………. 3-6
Exhibit 3-4: Global vascular stent sales combined market forecast, by country/region ($m), 2016-21 …………………………………………………… 3-8
Exhibit 3-5: Drivers and limiters of growth of the vascular stents market ……….. 3-13
Exhibit 3-6: Average sale prices of vascular stents in 2017 …………………………. 3-15
Exhibit 3-7: Global bare-metal stents market, share by supplier, 2016 ………….. 3-18
Exhibit 3-8: Global drug-eluting stents market, share by supplier, 2016 …………. 3-19
Exhibit 3-9: US vascular stent implantation, procedure volumes forecast (000s), 2016-21 ……………………………………………………………………. 3-22
Exhibit 3-10: US vascular stent sales combined market forecast, by product segment ($m), 2016-21 …………………………………………………………. 3-24
Exhibit 3-11: US bare-metal stents market forecast, by type ($m), 2016-21 …….. 3-26
Exhibit 3-12: US bare-metal stents market, share by supplier, 2016 ……………….. 3-27
Exhibit 3-13: US drug-eluting stents market forecast, by type ($m), 2016-21 …… 3-29
Exhibit 3-14: US drug-eluting stents market, share by supplier, 2016 ……………… 3-30
Exhibit 3-15: 5EU coronary vascular stent implantation, procedure volumes forecast, by country (000s), 2016-21 ………………………………………. 3-33
Exhibit 3-16: 5EU peripheral vascular stent implantation, procedure volumes forecast, by country (000s), 2016-21 ………………………………………. 3-35
Exhibit 3-17: 5EU vascular stent sales combined market forecast, by product segment ($m), 2016-21 …………………………………………………………. 3-38
Exhibit 3-18: 5EU bare-metal stents market forecast, by type ($m), 2016-21 …… 3-40
Exhibit 3-19: 5EU bare-metal stents market, share by supplier, 2016 ……………… 3-41
Exhibit 3-20: 5EU drug-eluting stents market forecast, by type ($m), 2016-21 …. 3-43
Exhibit 3-21: 5EU drug-eluting stents market, share by supplier, 2016 ……………. 3-44
Exhibit 3-22: Japan vascular stent sales combined market forecast, by product segment ($m), 2016-21 …………………………………………………………. 3-45
Exhibit 3-23: Japan coronary stent implantation, procedure volumes forecast (000s), 2016-21 ……………………………………………………………………. 3-47
Exhibit 3-24: Japan bare-metal stents market forecast, by type ($m), 2016-21 … 3-49
Exhibit 3-25: Japan bare-metal stents market, share by supplier, 2016 …………… 3-50
Exhibit 3-26: Japan drug-eluting stents market forecast, by type ($m), 2016-21 .. 3-51
Exhibit 3-27: Japan drug-eluting stents market, share by supplier, 2016 …………. 3-52
Exhibit 3-28: RoW vascular stent sales combined market forecast, by product segment ($m), 2016-21 …………………………………………………………. 3-53
Exhibit 3-29: RoW bare-metal stents market forecast, by type ($m) 2016-21 …… 3-58
Exhibit 3-30: RoW bare-metal stents market, share by supplier, 2016 …………….. 3-59
Exhibit 3-31: RoW drug-eluting stents market forecast, by type ($m), 2016-21 … 3-60
Exhibit 3-32: RoW drug-eluting stents market, share by supplier, 2016 …………… 3-62

APPENDIX: COMPANY LISTING ……………………………………………………………… A-1